Acorda Therapeutics, Inc. (ACOR): Price and Financial Metrics


Acorda Therapeutics, Inc. (ACOR)

Today's Latest Price: $0.76 USD

0.01 (1.23%)

Updated May 22 4:00pm

Add ACOR to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 336 in Biotech

See all "A" rated Strong Buy stocks

ACOR Stock Summary

  • In terms of twelve month growth in earnings before interest and taxes, Acorda Therapeutics Inc is reporting a growth rate of 33,087.73%; that's higher than 99.93% of US stocks.
  • Revenue growth over the past 12 months for Acorda Therapeutics Inc comes in at -56.92%, a number that bests only 2.89% of the US stocks we're tracking.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for ACOR comes in at 169.49% -- higher than that of 97.38% of stocks in our set.
  • Stocks that are quantitatively similar to ACOR, based on their financial statements, market capitalization, and price volatility, are CANG, MOMO, NOW, CHGG, and NINE.
  • ACOR's SEC filings can be seen here. And to visit Acorda Therapeutics Inc's official web site, go to www.acorda.com.
ACOR Daily Price Range
ACOR 52-Week Price Range

ACOR Stock Price Chart More Charts


ACOR Price/Volume Stats

Current price $0.76 52-week high $10.97
Prev. close $0.75 52-week low $0.70
Day low $0.72 Volume 1,643,384
Day high $0.76 Avg. volume 2,095,318
50-day MA $0.92 Dividend yield N/A
200-day MA $1.94 Market Cap 36.26M

Acorda Therapeutics, Inc. (ACOR) Company Bio


Acorda Therapeutics is a biotechnology company focused on developing therapies that restore function and improve the lives of people with neurological disorders. The company was founded in 1995 and is based in Ardsley, New York.


ACOR Latest News Stream


Event/TimeNews Detail
Loading, please wait...

ACOR Latest Social Stream


Loading social stream, please wait...

View Full ACOR Social Stream

Latest ACOR News From Around the Web

Below are the latest news stories about Acorda Therapeutics Inc that investors may wish to consider to help them evaluate ACOR as an investment opportunity.

DexCom & Domino's Pizza Set to Join S&P 500; Salesforce.com to Join S&P 100; STORE Capital to Join S&P MidCap 400; Capri Holdings to Join S&P SmallCap 600

S&P; Dow Jones Indices will make the following changes to the S&P; 500, S&P; 100, S&P; MidCap 400, and S&P; SmallCap 600 effective prior to the opening on Tuesday, May 12:

Yahoo | May 6, 2020

Acorda (ACOR) Q1 Earnings Lag Estimates, Revenues Fall Y/Y

Acorda's (ACOR) earnings and revenues fall shy of estimates in the first quarter of 2020. The company withdraws revenue view for its Parkinson's disease drug Inbrija due to the ongoing COVID-19 pandemic.

Yahoo | May 6, 2020

Acorda Reports First Quarter 2020 Financial Results and Provides Business Update

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) today provided a business update and reported its financial results for the first quarter ended March 31, 2020. “As we continue navigating the unprecedented operating environment created by COVID-19, our entire team remains focused on ensuring that the Parkinson’s disease and multiple sclerosis communities have continued access to Acorda’s critical medications,” said Ron Cohen, M.D., Acorda's President and Chief Executive

Business Wire | May 5, 2020

Acorda Therapeutics (ACOR) Reports Q1 Loss, Misses Revenue Estimates

Acorda (ACOR) delivered earnings and revenue surprises of -45.71% and -28.58%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

Zacks Investment Research | May 5, 2020

Acorda First Quarter 2020 Update: Webcast/Conference Call Scheduled for May 5, 2020

ARDSLEY, N.Y.--(BUSINESS WIRE)--Acorda Therapeutics, Inc. (NASDAQ: ACOR) will host a conference call and webcast in conjunction with its first quarter 2020 update and financial results on Tuesday, May 5 at 4:30 p.m. ET. To participate in the conference call, please dial (833) 236-2756 (domestic) or (647) 689-4181 (international) and reference the access code 7999873. The presentation will be available on the Investors section of www.acorda.com. A replay of the call will be available from 8:30 p

Business Wire | April 28, 2020

Read More 'ACOR' Stories Here

ACOR Price Returns

1-mo -26.57%
3-mo -42.42%
6-mo -56.57%
1-year -92.52%
3-year -94.67%
5-year -97.51%
YTD -62.75%
2019 -86.91%
2018 -27.37%
2017 14.10%
2016 -56.05%
2015 4.67%

Continue Researching ACOR

Here are a few links from around the web to help you further your research on Acorda Therapeutics Inc's stock as an investment opportunity:

Acorda Therapeutics Inc (ACOR) Stock Price | Nasdaq
Acorda Therapeutics Inc (ACOR) Stock Quote, History and News - Yahoo Finance
Acorda Therapeutics Inc (ACOR) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.773 seconds.